Cargando…

Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion

Detalles Bibliográficos
Autores principales:	Gaule, Marina, Pesoni, Camilla, Quinzii, Alberto, Zecchetto, Camilla, Casalino, Simona, Merz, Valeria, Contarelli, Serena, Pietrobono, Silvia, Vissio, Elena, Molinaro, Luca, Manzin, Enrica, Volpatto, Roberta, Vellani, Giorgio, Melisi, Davide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769132/ https://www.ncbi.nlm.nih.gov/pubmed/35005993 http://dx.doi.org/10.1200/PO.21.00400

Ejemplares similares

Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer
por: Merz, Valeria, et al.
Publicado: (2022)

Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab
por: Zecchetto, Camilla, et al.
Publicado: (2023)

Targeting KRAS: The Elephant in the Room of Epithelial Cancers
por: Merz, Valeria, et al.
Publicado: (2021)

Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer
por: Cavaliere, Alessandro, et al.
Publicado: (2019)

YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer
por: Bencivenga, Maria, et al.
Publicado: (2023)

Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
por: Merz, Valeria, et al.
Publicado: (2020)

A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal–gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial
por: Merz, Valeria, et al.
Publicado: (2020)

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review
por: Isaka, Yuri, et al.
Publicado: (2023)

The Multifaceted Role of TGF-β in Gastrointestinal Tumors
por: Sabbadini, Fabio, et al.
Publicado: (2021)

Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer
por: Carbone, Carmine, et al.
Publicado: (2018)

Prevalence of conduct disorder in schoolchildren of Kanke
por: Sarkhel, Sujit, et al.
Publicado: (2006)

HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies
por: Contarelli, Serena, et al.
Publicado: (2020)

A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib
por: Pietrobono, Silvia, et al.
Publicado: (2021)

Progressive renal insufficiency related to ALK inhibitor, alectinib
por: Nagai, Kojiro, et al.
Publicado: (2018)

Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells
por: Furugaki, Koh, et al.
Publicado: (2021)

ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib
por: Sagawa, Ray, et al.
Publicado: (2018)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)

STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib
por: Nagasaka, Misako, et al.
Publicado: (2020)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021)

Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
por: Satoh, Hironori, et al.
Publicado: (2021)

STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib
por: Kelly, Andrew D., et al.
Publicado: (2021)

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2023)

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
por: Watanabe, Satoshi, et al.
Publicado: (2022)

Kank attenuates actin remodeling by preventing interaction between IRSp53 and Rac1
por: Chandra Roy, Badal, et al.
Publicado: (2009)

Kank Is an EB1 Interacting Protein that Localises to Muscle-Tendon Attachment Sites in Drosophila
por: Clohisey, Sara M. R., et al.
Publicado: (2014)

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
por: Tran, Phu N., et al.
Publicado: (2016)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
por: Addeo, Alfredo, et al.
Publicado: (2018)

Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC
por: Peng, Ling, et al.
Publicado: (2021)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

The ALK inhibitors, alectinib and ceritinib, induce ALK‐independent and STAT3‐dependent glioblastoma cell death
por: Kawauchi, Daisuke, et al.
Publicado: (2021)

A circulating T(H)2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma
por: Piro, Geny, et al.
Publicado: (2017)

Correction: Kank Is an EB1 Interacting Protein that Localises to Muscle-Tendon Attachment Sites in Drosophila
Publicado: (2014)

Talin-KANK1 interaction controls the recruitment of cortical microtubule stabilizing complexes to focal adhesions
por: Bouchet, Benjamin P, et al.
Publicado: (2016)

Evolutionary and developmental analysis reveals KANK genes were co-opted for vertebrate vascular development
por: Hensley, Monica R., et al.
Publicado: (2016)

HSP70 Ameliorates Septic Lung Injury via Inhibition of Apoptosis by Interacting with KANK2
por: Pei, Qing, et al.
Publicado: (2022)

The structural basis of the talin–KANK1 interaction that coordinates the actin and microtubule cytoskeletons at focal adhesions
por: Li, Xingchen, et al.
Publicado: (2023)

OR04-02 KANK1 Deficiencies Underlie A Subset of Male Congenital Genitourinary Anomalies
por: Lamb, Dolores J, et al.
Publicado: (2023)

The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis
por: Fan, Junsheng, et al.
Publicado: (2018)

Alectinib treatment response in lung adenocarcinoma patient with novel EML4‐ALK variant
por: Song, Peng, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1suiabuc7k9ttq6g9cq4748cv5